Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant

E Nikolousis, S Robinson, S Nagra, C Brookes, F Kinsella, S Tauro, S Jeffries, M Griffiths, P Mahendra, M Cook, S Paneesha, R Lovell, B Kishore, S Chaganti, R Malladi, M Raghavan, P Moss, D Milligan, Charles Craddock

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

In this multicentre retrospective study we have studied the impact of T cell chimerism on the outcome of 133 patients undergoing an alemtuzumab based reduced intensity conditioning allograft (RIC). The median age of the patients was 50 years (range 42-55 years). 77 patients were transplanted using an HLA identical sibling donor while 56 patients received a fully matched volunteer unrelated donor graft. 64 patients had a lymphoid malignancy and 69 were transplanted for a myeloid malignancy. 38 patients (29%) relapsed with no significant difference in risk of relapse between patients developing full donor and mixed donor chimerism in the T-cell compartment on D+90 and D+180 post transplant. Day 90 full donor T cell chimerism correlated with an increased incidence of acute GVHD according to NIH criteria (p=0.0004) and the subsequent development of chronic GVHD. Consistent with previous observations, our results confirmed a correlation between the establishment of T cell full donor chimerism and acute GVHD in T deplete RIC allografts. However our study failed to identify any correlation between T cell chimerism and relapse risk and challenge the use of pre-emptive donor lymphocyte infusions (DLI) in patients with mixed T cell chimerism transplanted using an alemtuzumab based RIC regimen.
Original languageEnglish
Pages (from-to)561-5
Number of pages5
JournalLeukemia Research
Volume37
Issue number5
DOIs
Publication statusPublished - May 2013

Bibliographical note

Copyright © 2013 Elsevier Ltd. All rights reserved.

Fingerprint

Dive into the research topics of 'Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant'. Together they form a unique fingerprint.

Cite this